While these strategies highlight the versatility of STAT3 inhibitors, several challenges remain, including overlapping toxicities, potential resistance mechanisms, and tumor heterogeneity, which necessitate personalized treatment approaches. This evidence concerns the gene STAT3 and neoplasm.